FDA gives AstraZeneca extension on cancer drug application
AstraZeneca
10,292.00p
16:49 14/11/24
1.46%
148.00p
The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Dow Jones I.A.
43,750.86
04:30 15/10/20
n/a
n/a
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Merck & Co. Inc.
$98.36
11:10 14/11/24
-0.14%
-$0.14
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
Both companies said they would continue to work with the FDA to facilitate the completion of the agency's review.